Dr. Yasmin Hurd

Yasmin L. Hurd, PhD, is Ward-Coleman Chair of Translational Neuroscience and professor of psychiatry, neuroscience, and pharmacological sciences at the Icahn School of Medicine at Mount Sinai, and director of the Addiction Institute of Mount Sinai. A translational neuroscientist, Hurd is best known for a 2019 double-blind, randomized, placebo-controlled trial published in the American Journal of Psychiatry, "Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder" (PMID 31109198), which found that 400 mg and 800 mg oral CBD reduced cue-induced craving and anxiety in individuals with heroin use disorder, with effects persisting up to one week after dosing. Her laboratory has also produced influential preclinical and human-cohort research on prenatal and adolescent cannabis exposure, including epigenetic and neurodevelopmental effects on dopaminergic circuitry. Hurd previously held a faculty appointment at Karolinska Institute and has served on NIDA's Board of Scientific Counselors. → See also: Cannabidiol, Opioid use disorder.